Pfizer, Inc.(PFE) - Stock detail

Pfizer, Inc.

US
PFE
Pfizer Inc.(Listing date: 01/17/1944)

Pfizer Inc. was incorporated under the laws of Delaware on June 2, 1942. It is a research-based global biopharmaceutical company. Using science and global resources, the company brings therapies that extend and significantly improve people's lives through the discovery, development, manufacturing and distribution of healthcare products, including innovative medicines and vaccines. The company operates in both developed and emerging markets, committed to advancing health, prevention, treatment and cure for the world's most feared diseases of our time. It collaborates with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare services worldwide.

🎯 Pfizer, Inc. (PFE) 💰 Analysis Report 📅 Generated: 2026-06-03 17:44:32 ET

Investment Analysis: Pfizer, Inc. (PFE)

1. Investment Recommendation: BUY

2. Target Price: $30.00 (US Dollar)

  • Expected Increase: +18.4% from current price of $25.34
  • Price Range for Accumulation: $25.15 - $26.00
  • Stop-Loss Price: $24.90

3. Confidence Level: 0.75 (High-Moderate)

4. Risk Score: 0.40 (Moderate-Low Risk)

5. Detailed Reasoning:

Fundamental Valuation Support:

  • Deep Value Proposition: Current forward P/E of ~9x represents significant undervaluation for a pharmaceutical leader with 74.33% gross margins and strong cash flow generation. The market is pricing Pfizer as a no-growth company while ignoring pipeline potential.
  • Dividend Floor: The high dividend yield (implied 4.2%-6.7% range) provides downside protection and attracts income investors, creating a natural price floor.
  • Fair Value Calculation: Based on fundamental analysis, a re-rating to a more reasonable forward P/E of 12-14x (vs. current ~9x) justifies a target price of $30.00.

Positive Catalysts from Recent News:

  • ASCO 2026 Data Validation: Positive Phase 3 results for BRAFTOVI (BREAKWATER trial) in metastatic colorectal cancer and TALZENNA (TALAPRO-3 study) in prostate cancer represent material de-risking of the oncology pipeline.
  • Strategic Partnership: The $10.5B Innovent Biologics collaboration provides access to 12 early-stage oncology programs, diversifying research risk at milestone-driven costs.
  • Upcoming Catalysts: 2026 is catalyst-rich with obesity drug (danuglipron) data and regulatory decisions that could drive multiple re-ratings.

Technical Analysis Indicates Oversold Condition:

  • Extreme Oversold Signals: RSI(6) at 27.35, Williams %R at -88.89, CCI at -115.81, and KDJ J-value at 1.03 all suggest selling exhaustion.
  • Bollinger Band Support: Current price ($25.34) trades near the lower Bollinger Band ($25.16), historically a zone for mean-reversion bounces.
  • Weak Trend Strength: ADX of 12.17 indicates the downtrend lacks strong directional force, increasing probability of reversal.

Risk Mitigation Factors:

  • Margin of Safety: Single-digit P/E provides substantial downside protection even if growth materializes slower than expected.
  • Conservative Entry Strategy: Recommend scaling into position rather than lump-sum investment, using the oversold condition for initial entry.
  • Clear Risk Management: Stop-loss at $24.90 limits downside to 1.7% from initial entry point.

Historical Context Alignment:

  • The current setup mirrors classic value investment opportunities where extreme pessimism (reflected in technical downtrend) meets improving fundamentals (validated pipeline data).
  • The dividend yield provides compensation while waiting for the valuation gap to close.

Investment Timeline:

  • Short-term (1-3 months): Expect consolidation and gradual move toward $27.00 as oversold condition resolves.
  • Medium-term (3-6 months): Target $30.00 as market recognizes pipeline value and re-rates earnings multiple.
  • Long-term (6-12 months): Potential for $33.00+ if obesity pipeline delivers positive data and oncology assets gain commercial traction.

Conclusion: Pfizer represents a compelling risk-reward opportunity where significant bad news appears priced in, while recent positive developments create asymmetric upside potential. The combination of deep value, high yield, validated pipeline catalysts, and technical oversold conditions supports a BUY recommendation with a $30.00 target price. ✅ Analysis Complete